Karin Wirdefeldt1,2, Per Odin3,4, Dag Nyholm5. 1. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Solna, Sweden. 2. Department of Clinical Neuroscience, Karolinska Institutet, Solna, Sweden. 3. Department of Neurology, Skåne University Hospital, Lund, Sweden. 4. Klinikum-Bremerhaven, Bremerhaven, Germany. 5. Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden. dag.nyholm@neuro.uu.se.
Abstract
BACKGROUND: Levodopa-carbidopa intestinal gel (LCIG) is available in several countries for the treatment of advanced levodopa-responsive Parkinson's disease (PD) with severe motor fluctuations and dyskinesia when other treatments have not given satisfactory results. OBJECTIVE: Our objective was to summarize the present evidence base for LCIG therapy through a systematic review of the literature. METHODS: Studies were identified from the PubMed and EMBASE databases up to 12 March 2016 using the following search terms: Parkinson disease, duodopa, levodopa/carbidopa intestinal gel, levodopa-carbidopa intestinal gel, LCIG, l-dopa infusion, levodopa infusion, duodenal l-dopa infusion, and duodenal levodopa infusion. Data extraction focused on whether LCIG therapy improves motor and non-motor outcomes as well as quality of life in PD patients compared with conventional therapy, apomorphine infusion, or deep brain stimulation. Randomized controlled trials (RCTs) and observational studies, with or without a control group, that included more than ten patients were included. The search was limited to peer-reviewed articles published in full in the English language and involving humans. RESULTS: Infusion of LCIG reduced "off" time, increased "on" time without increasing troublesome dyskinesias, and improved quality of life in three RCTs (one double-blind). Open-label follow-ups confirm these findings. The data evaluating long-term efficacy and safety are still limited. CONCLUSIONS: The quality of evidence that LCIG is effective in reducing fluctuating motor symptoms and improving quality of life is moderate. Quality of evidence for reduction of non-motor symptoms is very low. Safety issues mainly relate to the intestinal infusion system. LCIG might be a useful treatment option in PD patients with severe motor fluctuations.
BACKGROUND:Levodopa-carbidopa intestinal gel (LCIG) is available in several countries for the treatment of advanced levodopa-responsive Parkinson's disease (PD) with severe motor fluctuations and dyskinesia when other treatments have not given satisfactory results. OBJECTIVE: Our objective was to summarize the present evidence base for LCIG therapy through a systematic review of the literature. METHODS: Studies were identified from the PubMed and EMBASE databases up to 12 March 2016 using the following search terms: Parkinson disease, duodopa, levodopa/carbidopa intestinal gel, levodopa-carbidopa intestinal gel, LCIG, l-dopa infusion, levodopa infusion, duodenal l-dopa infusion, and duodenal levodopa infusion. Data extraction focused on whether LCIG therapy improves motor and non-motor outcomes as well as quality of life in PDpatients compared with conventional therapy, apomorphine infusion, or deep brain stimulation. Randomized controlled trials (RCTs) and observational studies, with or without a control group, that included more than ten patients were included. The search was limited to peer-reviewed articles published in full in the English language and involving humans. RESULTS: Infusion of LCIG reduced "off" time, increased "on" time without increasing troublesome dyskinesias, and improved quality of life in three RCTs (one double-blind). Open-label follow-ups confirm these findings. The data evaluating long-term efficacy and safety are still limited. CONCLUSIONS: The quality of evidence that LCIG is effective in reducing fluctuating motor symptoms and improving quality of life is moderate. Quality of evidence for reduction of non-motor symptoms is very low. Safety issues mainly relate to the intestinal infusion system. LCIG might be a useful treatment option in PDpatients with severe motor fluctuations.
Authors: Prashanth Reddy; Pablo Martinez-Martin; Alexandra Rizos; Anne Martin; Guy C Faye; Ian Forgacs; Per Odin; Angelo Antonini; K Ray Chaudhuri Journal: Clin Neuropharmacol Date: 2012 Sep-Oct Impact factor: 1.592
Authors: S E Pålhagen; N Dizdar; T Hauge; B Holmberg; R Jansson; J Linder; D Nyholm; O Sydow; M Wainwright; H Widner; A Johansson Journal: Acta Neurol Scand Date: 2012-06-12 Impact factor: 3.209
Authors: C Warren Olanow; Karl Kieburtz; Per Odin; Alberto J Espay; David G Standaert; Hubert H Fernandez; Arvydas Vanagunas; Ahmed A Othman; Katherine L Widnell; Weining Z Robieson; Yili Pritchett; Krai Chatamra; Janet Benesh; Robert A Lenz; Angelo Antonini Journal: Lancet Neurol Date: 2013-12-20 Impact factor: 44.182
Authors: Florence C F Chang; Vu Kwan; David van der Poorten; Neil Mahant; Nigel Wolfe; Ainhi D Ha; Jane M Griffith; David Tsui; Samuel D Kim; Victor S C Fung Journal: J Clin Neurosci Date: 2016-01-14 Impact factor: 1.961
Authors: Alfonso Fasano; Angelo Antonini; Regina Katzenschlager; Paul Krack; Per Odin; Andrew H Evans; Thomas Foltynie; Jens Volkmann; Marcelo Merello Journal: Mov Disord Clin Pract Date: 2020-05-04